We examined the distribution of genes of aminoglycosidemodifying enzymes and 16S rRNA methylases in multidrug-resistant Acinetobacter baumannii to explore the association of these genes with drug resistance. Strains isolated from clinical specimens were screened using an automatic microbial identification system, and 9 aminoglycosidemodifying enzyme and 6 16S rRNA methylase genes were analyzed using polymerase chain reaction and verified by DNA sequencing. Next, sequence alignment was carried out using the Chromas software and a susceptibility test was performed using the Kirby-Bauer disk diffusion method. Genes encoding aminoglycoside-modifying enzymes were detected in all 20 strains of multidrug-resistant A. baumannii. The positive rates of aac(3')-I, aac(6')-Ib, ant(3'')-I, and aph(3')-I were 90.0, 90.0, 85.0, and 35.0%, respectively. However, genes encoding 16S rRNA methylases were not positively detected in the 20 strains of multidrugresistant A. baumannii. The resistance of multidrug-resistant A. baumannii ©FUNPEC-RP www.funpecrp.com.br Genetics and Molecular Research 13 (2): 3842-3849 (2014) Resistance of multidrug-resistant Acinetobacter baumannii may be associated with aminoglycoside-modifying enzyme genes but not with 16S rRNA methylase genes.
INTRODUCTION
Acinetobacter baumannii is a parasite that is widely distributed in nature and in the human body. Because of extensive application of broad-spectrum antibiotics, an increasing number of multi-drug resistant strains of A. baumannii have appeared, which have become important pathogens of nosocomial infection (Fishbain and Peleg, 2010; Gordon and Wareham, 2010; Hou et al., 2012) . These strains show strong resistance to the external environment and can acquire multidrug resistance quickly by carrying many movable genetic elements for multiple resistance genes (Golanbar et al., 2011; Taherikalani et al., 2011) . The increasing occurrence of drug-resistant A. baumannii has caused concern in global medicine (Baumgart et al., 2010; Tasbakan et al., 2011) .
b-Lactams drugs are bactericides used in the multiplication stage, whereas aminoglycoside are bactericides used during the rest period. It is commonly understood that these 2 drugs have a synergistic effect. Thus, a combination of aminoglycosides (such as Gentamicin) and b-lactams (such as Imipenem) has been commonly used for treating A. baumannii infections. However, due to its production of OXA-23-type b-lactamase, imipenem-resistant A. baumannii has become a worldwide problem (Mugnier et al., 2010; Poirel et al., 2010; Kim et al., 2012) . Along with the increasing rate of drug resistance to b-lactams, drug resistance to aminoglycoside is also increasing, and clinically isolated aminoglycoside-resistant strains have become common (Brigante et al., 2012) . There are 2 main reasons for Gram-negative bacilli resistance to aminoglycosides. The first is that aminoglycosides entering bacteria are modified by aminoglycoside-modifying enzymes and become non-functional. The second is that methylation of target sites is induced by 16S rRNA methylases, leading to decreased affinity of 16S rRNA for aminoglycosides (Galimand et al., 2000; Davis et al., 2010; Zhou et al., 2010) .
Regional differences in the drug resistance of bacteria have been observed; the resistance gene carried by some strains also varies from location to location. Genes encoding aminoglycoside-modifying enzymes and 16S rRNA methylase in multidrug-resistant A. baumannii should be examined to investigate their relationship to the development of drug resistance. In this study, 9 aminoglycoside-modifying enzyme genes and 6 16S rRNA methylase genes were investigated in 20 strains of multidrug-resistant A. baumannii isolated from the Lianyungang region in China. The objective of this study was to increase understanding of the prevalence of multidrug-resistant A. baumannii in this region, provide guidance for research and development of new drugs, and facilitate clinical anti-infection treatment and reasonable use of antimicrobial agents for early rehabilitation of patients.
MATERIAL AND METHODS

Collection of the strains
Twenty strains of multidrug-resistant A. baumannii were isolated from sputum specimens of patients hospitalized in the Second People's Hospital, Lianyungang, Jiangsu, China, from January 2011 to December 2011. This study was conducted in accordance with the Declaration of Helsinki and with approval from the Ethics Committee of the Second People's Hospital of Lianyungang City. Written informed consent was obtained from all participants.
Strain identification
Because biochemical identification methods cannot distinguish between A. baumannii and Acinetobacter calcoaceticus, strain identification was conducted using an automatic microbial identification system (Siemens Healthcare Diagnostics; Malvern, PA, USA) for initial screening and amplification of the gyrA and parC genes using a polymerase chain reaction (PCR) technique in this study. After DNA sequencing of the PCR products and matching their sequences against the National Center for Biotechnology Information database (www.ncbi.nlm.nih.gov), the strains confirmed as A. baumannii were selected for further analysis.
Susceptibility test
The NC31 Gram-negative bacteria identification and susceptibility board (Siemens) was used to preliminarily assess the minimum inhibitory concentration (MIC) susceptibility results of the strains against the 14 drugs recommended by the Clinical and Laboratory Standards Institute (CLSI), including piperacillin, cefotaxime, ceftazidime, ceftriaxone, cefepime, imipenem, ampicillin/sulbactam, ticarcillin/clavulanic acid, gentamicin, tobramycin, amikacin, ciprofloxacin, levofloxacin, and compounded sulfamethoxazole. Subsequently, the Kirby-Bauer disk diffusion method (Oxoid Microbiology Products; Basingstoke, UK) was used to verify multidrug resistance. Antimicrobial susceptibility determination was based on the criteria outlined in the 2011 edition of the CLSI. The Mueller-Hinton (M-H) medium was obtained from Oxoid Microbiology Products.
DNA extraction
One single colony of each strain was picked from the purified culture and transferred into a 0.5-mL EP tube containing 400 mL 200 ng/mL freshly prepared proteinase K. After incubation at 56°C for 2 h to destroy the bacterial membrane and release the DNA, the tube was then incubated at 95°C for 10 min to inactivate proteinase K. Before PCR, all DNA samples were stored at -20°C.
Gene detection
Nine aminoglycoside-modifying enzyme genes and 6 16S rRNA methylase genes were detected using PCR according to manufacturer instructions of the PCR kit (Wuxi Institute of Cloning and Genetic Technology; Jiangsu, China). All gene-specific primers were designed and provided by Zuhuang Mi, Department of Bioinformatics, Wuxi Institute of Cloning and Genetic Technology, Jiangsu, China (Table 1) .
DNA sequencing
Positive PCR products were sent to Shanghai Boshang Biological Technology, Ltd., Co. for DNA sequencing. An Applied Biosystems 3730xl DNA Sequencer (Applied Biosystems; Foster City, CA, USA) was used.
Sequence alignment
DNA sequences were read using the Chromas software and aligned using BLAST search tools.
RESULTS
Drug resistance of A. baumannii
The susceptibility of the 20 strains of A. baumannii against the 14 antibiotics was similar according to the results of two different susceptibility test methods ( Table 2 ). All strains were fully resistant to piperacillin, ceftazidime, ceftriaxone, cefepime, and imipenem. The resistance rate against aminoglycosides, fluoroquinolones, and trimethoprim-sulfamethoxazole was more than 90.0%. For instance, the resistance of all 20 strains of A. baumannii against gentamicin, tobramycin, amikacin, and other aminoglycoside drugs was more than 90%. All 20 strains of A. baumannii showed resistance to 3 or more different classes of antibiotics simultaneously; thus, they conformed to the criteria of multi-drug resistance.
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Aminoglycosides-modifying enzyme genes in the 20 strains of A. baumannii
All 9 aminoglycoside-modifying enzyme genes were positively detected, among which the positive rates of aac(3')-I, aac (6' (Table 3) . DNA sequencing results of the PCR products were confirmed using the BLASTn tool (www.ncbi.nlm.nih.gov/BLASTn) (Figure 1) . 
16S rRNA methylase genes in the 20 strains of A. baumannii
None of the 6 16S rRNA methylase genes was detected positively in the 20 strains of A. baumannii.
DISCUSSION
Since aminoglycosides (Streptomycin) were first identified 70 years ago, aminoglycoside drugs have been commonly used for treatment. Most aminoglycosides are natural antibacterial substances produced by microorganisms, but a few, such as amikacin and isepamicin, are semi-synthetic derivatives of natural compounds. Aminoglycosides are broad-spectrum bactericidal agents. They have killing effects on most pathogens and opportunistic pathogens isolated clinically, except for anaerobes. This may be because aminoglycosides carry protons, which can easily interact with the negative charge on a bacterial cell surface, facilitating binding to nucleic acids. When increasing numbers of aminoglycosides bind to the A site of the bacterial ribosome, which is not only the aminoacyl-tRNA binding site, but also the codonanticodon recognition region, mistranslation of mRNA into an amino acid sequence can occur, resulting in the production of abnormal proteins, and bacterial cell death.
The drug resistance of A. baumannii has become increasingly important and causes great difficulties in the clinical treatment of bacterial infections (Shahcheraghi et al., 2011; Doi, 2012; Wang et al., 2012) . The 20 strains of A. baumannii analyzed in this study were isolated from sputum specimens from in-patients. They were all insensitive to the commonly used cephalosporins, including imipenem, and the cephalosporin complex preparations. Their resistance to aminoglycosides, fluoroquinolones, and trimethoprim-sulfamethoxazole reached greater than 90%, among which resistance against gentamicin, tobramycin, amikacin, and other aminoglycoside-based drugs was more than 90%. Thus, the resistance of the 20 strains of A. baumannii isolated in this study is very alarming. Garnacho-Montero and Amaya-Villar (2010) found that polymyxin has a clear curative effect on multidrug-resistant A. baumannii. However, a study by Moffatt et al. (2010) showed that A. baumannii has heterogeneous resistance to polymyxin, and that the heterogeneous resistance strain can partially recover its sensitivity to other antibacterial drugs. Therefore, polymyxin combined with b-lactam antibiotics or tigecycline is a potential alternative for inhibiting A. baumannii, but this requires confirmation through large-scale clinical studies.
Aminoglycoside-modifying enzymes can be divided into 3 categories according to their functions: 1) acetyltransferase (AACs), whose related genes include aac(3)-I, aac(3)-II, and aac(6')-Ib, among others, and can cause acetylation of free hydroxyl groups; 2) phosphotransferase (APH), including aph(3')-I, leads to phosphorylation of free hydroxyl groups; 3) nucleotide transferase (ANT), also known as adenosine transferase (AAD), includes ant(3'')-I and ant(2'')-I, which can lead to nucleosidation of free hydroxyl groups. More than 30 aminoglycoside-modifying enzyme genes and 7 16S rRNA methylase genes have been identified to date. In Europe, the most commonly observed aminoglycoside-modifying enzyme genes include aac(3)-I, aac(3)-II, aac(6')-Ib, aph(3')-I, and ant(3'')-I (Nemec et al., 2004) . In this study, we detected 9 aminoglycoside-modifying enzyme genes from all 20 strains of A. baumannii. We found that all of the 20 strains of A. baumannii carried at least one type of aminoglycoside-modifying enzyme gene, among which both aac(3')-I and aac(6')-Ib showed a positive rate of 90% (18/20), ant(3'')-I showed a positive rate of 85% (17/20), and aph(3')-I showed a positive rate of 35% (7/20). These results are consistent with those of Nemec et al. (2004) . Based on the positive patterns of the 20 strains of A. baumannii shown in Table 3 , most A. baumannii possess ≥2 aminoglycoside-modifying enzyme genes, except for the 2 strains possessing only one gene, aac(3')-I. Seven 16S rRNA methylase genes have been previously identified, including armA, rmtA, rmtB, rmtC, rmtD, rmtE, and npmA (Davis et al., 2010; Zhou et al., 2010) . The rmtE gene was recently isolated from Escherichia coli from bovine (Davis et al., 2010) . However, in the present study, the 6 16S rRNA methylase genes tested were undetected in the 20 strains of A. baumannii. This is different from the results of previous studies (Davis et al., 2010; Zhou et al., 2010) , which may be related to regional differences. A cluster analysis conducted by Chinese researchers showed that aminoglycosidemodifying enzyme genes and 16S rRNA methylase genes are often associated with genetic markers of moveable genetic elements (Kansakar et al., 2011) , i.e., these genes are removable rear-mediated genetic elements (Wu et al., 2009; Asadollahi et al., 2011) . This acquired resistance mechanism facilitates horizontal spread. Genomic studies have revealed that multidrugresistant A. baumannii is rich in the efflux pump gene (Rajamohan et al., 2010; Zhou et al., 2011) , and high expression of this gene plays an important role in the multidrug resistance of A. baumannii (Coyne et al., 2011) . In future studies, mobile genetic elements and the efflux pump will be further investigated to determine their correlation with multidrug resistance.
In conclusion, the multidrug resistance of A. baumannii isolated from in-patients of our hospital was related to aminoglycoside-modifying enzyme genes but not to 16S rRNA methylase genes.
